Kathy Tober Joins Quanta BioDesign, Ltd.
Kathy Tober, Ph.D.,
For immediate publication
Plain City, Ohio, January 22, 2020
Quanta BioDesign, Ltd., is pleased to announce that Kathy Tober, Ph.D., has joined us as Chief Client Development Officer, a newly created position within the company. In this position, Kathy will work closely with existing clients to understand their needs and to help them use dPEG® products more effectively, and she will find and develop new client relationships for Quanta BioDesign. Kathy has a B.A from Wittenburg University and a Ph.D. from The Ohio State University. Her experience includes over 20 years of NIH- and industry-sponsored research. She comes to Quanta BioDesign from The Ohio State University Wexner Medical Center, where she most recently served as manager of the clinical histology laboratory.
Kathy Tober, Ph.D., Chief Client Development Officer, Quanta BioDesign, Ltd.
“I am thrilled to be part of Quanta Biodesign, Ltd., and I look forward to contributing to the continued success of the company. Having watched the devastating effects of end-stage cancer on so many of my loved ones and my strong working knowledge of both basic and clinical science, I hope to enhance our presence in both the pharmaceutical and life science marketplace.” Kathy Tober, Ph.D., Chief Client Development Officer
Kathy loves to travel
Kathy and her husband, Pete, love to travel. This love of traveling takes them around the country to visit friends, a still-expanding extended family that includes ten great-nieces and nephews, and their daughter, who is a collegiate volleyball player. In her position as Chief Client Development Officer, Kathy will have numerous additional opportunities to exercise her passion for travel as she meets with current and prospective clients around the world.
Quanta BioDesign is thrilled to have Dr. Kathy Tober join us to help us grow the business by showcasing how our dPEG® technology adds value to products and applications in the pharmaceutical, clinical diagnostics, and life sciences markets.
Founded in 1997 by Paul D. Davis, Ph.D., and renamed in 1999, Quanta BioDesign, Ltd. is a made-in-America success story. The company is the world’s leading developer, innovator, and manufacturer of single molecular weight, discrete chain-length polyethylene glycol derivatives, which the company sells under the dPEG® tradename. These monodispersed PEG products are transforming biotechnology, pharmaceuticals, medical diagnostics, theranostics, nanotechnology, and many other areas of science and medicine. Located in Plain City, Ohio, a suburb of Ohio’s capital city, Columbus, Quanta BioDesign’s operations are based entirely in the United States. Sales of dPEG® products are global. Over 1,200 scientific journal articles report the successful use of Quanta BioDesign’s dPEG® products. Also, the company’s products have been mentioned or used in more than 600 patent applications worldwide.